Time to reassess the value of HRT

December 13, 2001

Editorial: Hormone replacement therapy and the breast BMJ Volume 323, pp 1381-2

It may be time to reassess the value of hormone replacement therapy, following evidence that it reduces the effectiveness of breast screening and causes breast cancer in women over the age of 50, says a leading breast surgeon in this week's BMJ. Increasing numbers of women in their 50s and 60s are using hormone replacement therapy to alleviate menopausal symptoms, yet the effect of long term use of these agents in women aged over 50 on the breast is only now becoming apparent.

In many women, hormone replacement therapy increases breast density. This affects both the sensitivity and specificity of breast screening because the effectiveness of breast screening depends on the decreasing breast density normally seen with age.

In countries where hormone replacement therapy is widely used, this reduction in the sensitivity of breast screening could undermine the capacity of national breast screening programmes to reduce deaths due to breast cancer, explains the author.

Studies of early hormone replacement therapy reported an increased risk of breast cancer for each year of use. More recent studies have reported significantly higher levels of risk in women taking combined hormone preparations compared with women taking oestrogen alone.

The evidence that hormone replacement therapy reduces the effectiveness of breast screening and causes breast cancer in women over the age of 50 is clear, says the author. The challenge for clinicians is to control menopausal symptoms while limiting these unwanted effects, he concludes.
-end-


BMJ

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.